Lannett Holdings, Inc.

Celgene filed an ANDA patent infringement action against Lannett over generic thalidomide (Lannett ANDA No. 206601), asserting fifteen patents. The parties settled in 2017, with Lannett converting its Paragraph IV certification on the '745 patent to a Paragraph III certification and receiving a license to market generic thalidomide as of August 1, 2019. The narrative could not confirm that U.S. 7,959,566 was among the fifteen asserted patents.

Thalidomide ANDA litigation listed on the US 7,230,012 record. Outcome not established in the retrieved sources.

Celgene's Hatch-Waxman ANDA suit against Lannett Holdings, filed in D.N.J. The narrative lists it among verified litigation naming US 6,869,399, and notes that the Barr and Lannett suits asserted a bundle of Celgene thalidomide patents including '501, '720, '977, and '784. The outcome on the '399 patent is unconfirmed.

Celgene's ANDA/paragraph IV case against Lannett over generic thalidomide, in which Celgene asserted fifteen patents. The narrative could not confirm that '018 was among the asserted patents, although it was among Celgene's Orange Book-listed Thalomid patents. The case settled in October 2017 with a license permitting generic entry as of August 1, 2019.

Celgene sued Lannett in an ANDA/Hatch-Waxman case over generic THALOMID; Lannett counterclaimed for monopolization/sham litigation. Google Patents lists US 6,561,976 as involved. Settled.